Copenhagen, 2015-11-26 12:35 CET (GLOBE NEWSWIRE) -- 26 November 2015 – Zealand informs that pursuant to Section 29 of the Danish Securities Act, cf. Executive order no. 1256 of 4 November 2015 on major shareholders and the Danish Companies Act section 55, cf. section 56, the company has received a major shareholder announcement from Bpi Groupe, 27-31 Avenue du Général Leclerc, 94700 Maisons-Alfort, France (French registration no. 507 523 678 R.C.S. Créteil).
Bpi Group has announced to Zealand that following Zealand’s capital increase as effected on 8 September 2015 (Company announcement no. 38-15), Bpi Groupe’s indirect holding, (via its subsidiaries CDC Entreprises Capital Investissement and Bpi France Participation) of nominally DKK 1,190,215 shares of nominally DKK 1 each and 1,190,215 voting rights in Zealand Pharma A/S corresponds to less than 5.00 % of the company’s total share capital and voting rights.
●●●●●
For further information, please contact:
Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia® by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus®) which is on track for regulatory submission in the US in Q4 2015 and in the European Union in Q1 2016.
The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics.
The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www,zealandpharma.com or follow us on Twitter @ZealandPharma
